Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly NNC0195-0092 vs daily Norditropin FlexPro in previously treated adults with growth hormone deficiency
2014-000290-39Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Incidence of adverse events. Started Oct 2014; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2014-000290-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000290-39.